Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Partnered Content
Meet the Team
Ask the Analyst
RSS Feeds
Subscribe
Advertise
Contact Us
FAQs
Reports Store
UsernamePublicRestriction
Tags:
Pricing Debate Generic Drugs Legislation

CREATES Act Will Not Lead To Frivolous Lawsuits, Says AAM's Davis

  • Analysis

Executive Summary

Association for Accessible Medicines' Davis tries to counter concerns that the long-stalled measure would incentivize lawsuits against brand companies; witnesses at a House subcommittee hearing on drug pricing legislation also testified that the BLOCKING Act would create an overly broad and complicated framework for triggering 180-day exclusivity.

Table

View full table

Advertisement

Related Content

Pink Sheet
Trump FY 2020 Budget Renews Push To Reform 180-Day Exclusivity
Pink Sheet
Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA
Pink Sheet
REMS Abuse Website: Has It Changed The Behavior Of Innovators?
Pink Sheet
CREATES Act To Face Major Reshaping By Innovator-Friendly Amendments On Senate Floor
Pink Sheet
Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?

Topics

Related Companies

What to read next

Advertisement
Tags:
Pricing Debate Generic Drugs Legislation
UsernamePublicRestriction

Register

GB140160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By